{"name":"Phage Pharmaceuticals, Inc.","slug":"phage-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Syntropin","genericName":"Syntropin","slug":"syntropin","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Syntropin","genericName":"Syntropin","slug":"syntropin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPM3ZwRUtrMjRFcm0wb2VUbjBXZUFfQlRfaURsOGw1a3NRbzF5OGlTR2hwd0REMGUtanVQRVFPdEotTjBJMERXZFlMaHIyaW5leXphWVc1M3lQUVp4MERPY005Qm1RNi1WNE16ay1MZjQ1aVZsUzNBbUhBUFFVS3ZOdA?oc=5","date":"2026-02-24","type":"pipeline","source":"American Society for Microbiology","summary":"Phage Therapy: Past, Present and Future - American Society for Microbiology","headline":"Phage Therapy: Past, Present and Future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbFJFa19PTzBtRjRxaUlMWWJ2NjJIZ1Z3c3p2UndxektJOWVVelpoaVZ0dHdWeVdrN2p6OTVJVzF6RmlHaURMNDIzUFBVNTEzelBIOGdlTEFUalc0bW00eThkMXRNMFMtNFBkcTNXQnZfNkJQZDBhcTRtNWh1UXFqZ3B5bm1aVlYyZVVaMkNtVWJEcUNxYkkwUHlhakhxdjh5R3EyanU2R1RScWRyX1hlYll2dXFmei1Y?oc=5","date":"2025-11-17","type":"regulatory","source":"Clinical Leader","summary":"Phages As A Pharmaceutical: New EMA Guidance On Antimicrobial Drug Development - Clinical Leader","headline":"Phages As A Pharmaceutical: New EMA Guidance On Antimicrobial Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQT3ZuMDRTM1M3dnZzaW1OaDFNSlVNOXFaWHhjY29ZRDF3ekNuYTJEbVA3aHN0QmdTdmZoa2c0cWZZdV9TMG0zbTlqN1FENkNFQWdzM1EtVVNRaGJFeUo4R3dsZ3Zkcm5yOWZmaWVyUExlU2tQNkxqVC05RzJ1LVI3ZzlXZ0NNaG1KR0QyZG5oRERYR1lubXA3amY3X2x5R1JI?oc=5","date":"2025-11-10","type":"pipeline","source":"Yahoo Finance","summary":"Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California - Yahoo Finance","headline":"Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angel","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-30","type":"trial","source":"Express Pharma","summary":"Armata AP-SA02 shows promise for SAB in Phase IIa trial, underscoring growing potential of phage therapy: GlobalData - Express Pharma","headline":"Armata AP-SA02 shows promise for SAB in Phase IIa trial, underscoring growing potential of phage therapy: GlobalData","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxONXpTT2VERFAzNFBEUEdnR0lrQ1VCNzJiNTBPQU1TbnVUcWsyeDc4ZmdtQmVhTFI1UXVObGZZOVIzRm42ang1TEZkUmpJaWgzMmdfS0VMWUp5QUt6RW5hQU9sYjdNcEZqS0RKemJvaVJLYlNrUU16djV3bElreWJlUFZIX0pzQzcxRXIyWHNucDdORmM?oc=5","date":"2025-07-19","type":"pipeline","source":"MarketsandMarkets","summary":"Antibody Discovery Services Market Report 2025-2030, By Type, Technology, and Geo - MarketsandMarkets","headline":"Antibody Discovery Services Market Report 2025-2030, By Type, Technology, and Geo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQemE2RVlwYXIzYnZ3enRWT3Y3cVh6b2lHZjlLaDZYbjZReE1rbFp4QW5Gb0Q5cEsxVDlKcTdZc1VlZVAwTFBEbW8tSTRHUVpxMjVnNXBZWDUxMzNOTy04OTJSRGllaXl2MUViWHFsUlZab19DM0tqMV9LTTVrWHJJUWRVaFRDaHRjanNFNQ?oc=5","date":"2025-07-17","type":"pipeline","source":"IQVIA","summary":"The good virus – phage therapeutics - IQVIA","headline":"The good virus – phage therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOLTZUMnVZWlNkS2dkWnlXTFNBd3JkTGdWYmU0S0dkMFd6a3pheS02cy0tdVB3X25WT1FoS0NQMjZVSkFTZXF1QnpVZFllb1FEVkJqWUExTDRfYWFDOFp1eGJzUVNYV19RZk1QdnJIVzZMWi1nakg2X19PandDdkE4V0s0akFMcGdBT21QYzJndWZhNVBjM2drNHlXekU0Tjc3SHFEVjdWY2NYeHV6?oc=5","date":"2025-07-16","type":"pipeline","source":"news.biobuzz.io","summary":"21 Emerging Life Science Companies Fueling Maryland’s Biohealth Ecosystem - news.biobuzz.io","headline":"21 Emerging Life Science Companies Fueling Maryland’s Biohealth Ecosystem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBnS1ZhOC1lTFdBeXZWMUVBeDBsYXZuZU1fSmRLRlJleDB6MnphMlpsRWNMcGw4dlI3M3N3Wm43VFB5dEprdHdCRVBnUW02dnhHbmNpelgtUDhnNUJpdzJV?oc=5","date":"2025-05-30","type":"pipeline","source":"Nature","summary":"Antibiotics re-booted—time to kick back against drug resistance - Nature","headline":"Antibiotics re-booted—time to kick back against drug resistance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPQzdXZm1tUU5HMDFzVlpqTG9pQ0Via044a2QyVDJKUk5KcEJfakNIbkxkVWlZTVd0cU8zQlRzVV9lckpqZnZaWC1uX1dzT25iems4MndKQUhDakVkb2lEZE42Vmc3a21OWExYSEt1bElPTF96REJ4MWJBTzl2RndrcGZaaDJEQnpPcmhzWDUtd2NUUDZCN1lWbVJMbld2NmFFakxqQ3pTZnozQ0Y4b3l6V0IycHNYUExlbVVQYlJmWlZ1VE5PeVR5ZkZJd08xT3BnUGxIeWFIWGpCdmI0eVE?oc=5","date":"2025-05-14","type":"earnings","source":"prnewswire.com","summary":"Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - prnewswire.com","headline":"Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNbGJ1VUp6YkVQRG80U295Wml2T180akFDSTV2cFhYLWR5b1J5WWY5Vm8zbVRwc3dpVkZuLVFLcDlxNXQtRGczNGFvY2NramU1VzRNOVJQM3hlcnNjWTBET2RXRlpSMmFLdnc4d1VlMkVEY2tCWE16cGNTSUFjZWtYLW1JTi00OWVWMFAxWnlkNlBKd3hERW91LUVDdVNQVjBsNnBUZ3FmVmZLSUlQNDJWTDJuOUNLdw?oc=5","date":"2024-07-30","type":"pipeline","source":"Pharmaceutical Technology","summary":"Who are the leading innovators in bacteriophage therapy for the pharmaceutical industry? - Pharmaceutical Technology","headline":"Who are the leading innovators in bacteriophage therapy for the pharmaceutical industry?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxOeU0yT2VOM3VuVUJkMWh2Qmd0RFprZHZvb3BuXzViZlQ5X3VXUTdzM2FFTTNzdU5tM1NxMnVyN1dUZDE1WkRzTzJCLXB4d3Z4RzctZ0pua0R5LTdNdUxZTll2VjluMjk4QXdOYW9MejR2bW44WFNOamY0UGt2WDhfZ0h4SUR4Mk9XaXFYMzFTYkhFem5ncHhjREllbnRjQ2tQSlE0QmFaR1Z5UUhtaFpwcE5nenZXTERGcUZxN0liWnA1UlFLa3BYVEttMzdOQnZCQTkxaVhDc3ZHU1VfSnAzT3FVanFBcldIbDBvd3E0SVpOeFRPTFBGajNIWWJiclhxMjAzajB0emJIZnl1TkZENHBTZVZtUQ?oc=5","date":"2023-06-13","type":"pipeline","source":"businesswire.com","summary":"Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections - businesswire.com","headline":"Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPSWluaTFyWGNRamhKQ2xxOHJKZnhYSGVMSjVpN0w2ekp3YWxqdHA0TUI1OVNwd0xBYmRaaUVoNnBwZ3ZnM1JwaUdZa0RSa0E2ZlBXMkVzUl92Qjh1aVNrejdiTFVva3pfd0E0S09MVjhjX2FSZ0ZxbHU4NHVickJQOEVkcmJfS21rSnNET0VTdW1RLWJvcWd3MEYtNzJITm5q?oc=5","date":"2023-03-30","type":"pipeline","source":"Pharma Voice","summary":"Predator and prey: Harnessing phages to fight antibiotic resistance - Pharma Voice","headline":"Predator and prey: Harnessing phages to fight antibiotic resistance","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}